NovoCure Limited (NVCR)
Valuation Overview•Is NovoCure Limited Overvalued or Undervalued?
Trading at a discount to intrinsic cash flow value, implying pessimistic long-term market expectations.
Fragile underlying quality score of 40/100; weak margins or elevated debt leverage warrant caution.
Analysts remain bullish, forecasting further upside expansion with consensus targets suggesting solid gains.
Verdict: Average quality business weighed down by significant profitability concerns.
Wall Street is highly bullish, projecting significant upside. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
NVCR struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company demonstrates solid revenue growth (6.8% 3Y CAGR) paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-27.2%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $174.1M | +8.3% | +6.8% | +5.8% | +34.8% | |
| EBITDA | -$63.3M | — | -20.1% | — | — | |
| Net Income | -$71.1M | +19.2% | -13.8% | — | -2.0% | |
| EPS (Diluted) | $-0.62 | +21.8% | — | — | +0.9% | |
| Free Cash Flow | -$18.7M | -9.3% | — | — | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 75.2% | 75.6% | 76.8% | 71.8% |
| Operating Margin | -27.2% | -32.5% | -24.5% | -29.1% |
| Net Margin | -25.7% | -29.8% | -23.5% | -33.5% |
| FCF Margin | -7.1% | -14.2% | -6.0% | -18.6% |
| Quarter | EPS Est. | EPS Act. | Surprise | EPS | Rev |
|---|---|---|---|---|---|
| Q2'26Latest | $-0.51 | $-0.62 | -21.0% | ||
| Q1'26 | $-0.41 | $-0.22 | +46.3% | ||
| Q4'25 | $-0.42 | $-0.33 | +21.4% | ||
| Q3'25 | $-0.39 | $-0.36 | +7.7% | ||
| Q2'25 | $-0.47 | $-0.31 | +34.0% | ||
| Q1'25 | $-0.34 | $-0.61 | -79.4% | ||
| Q4'24 | $-0.34 | $-0.28 | +17.6% | ||
| Q3'24 | $-0.40 | $-0.31 | +22.5% |
Total return is -15.0% (1Y), lagging the benchmark by -40.0%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | +8.8% | -0.5% | — |
| 1Y | -15.0% | -40.0% | — |
| 3YCAGR | -31.3% | -45.6% | — |
| 5YCAGR | -42.0% | -52.1% | — |
| 10YCAGR | +2.0% | -8.6% | — |
The S&P 500 is at 31.3x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about NovoCure Limited (NVCR) valuation, health, and returns.
NovoCure Limited is estimated to be undervalued under our discounted cash flow framework. undervalued (implying +61.8% upside to DCF intrinsic value of $23.11)
NovoCure Limited has multiple valuation anchors: DCF Intrinsic Value: $23.11 | Wall Street Analyst Target: $33.00 (implying +131.1% upside). A convergence of these signals offers higher conviction.
NovoCure Limited displays fair financial health with a composite quality score of 40/100, supported by a Altman Z-Score of 0.3 (distress zone), Piotroski F-Score of 5/9, Return on Invested Capital (ROIC) of -16.4%.
NovoCure Limited does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
NovoCure Limited's current growth trajectory is Stable. The company achieved +8.3% 1Y revenue growth and +21.8% 1Y EPS growth, compared to its 3Y revenue CAGR of +6.8%.
Wall Street consensus is Buy based on 15 analysts, beating EPS expectations in 75% of recent quarters with a -1-quarter streak. The consensus price target represents a +131.1% change from current levels.
Investment risks for NovoCure Limited include: -45.7% 1-year max drawdown, high beta (2.00x market volatility), elevated distress risk. Volatility risk is characterized by a beta of 2.00x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.